K
Kuishu Ren
Researcher at AstraZeneca
Publications - 9
Citations - 1151
Kuishu Ren is an academic researcher from AstraZeneca. The author has contributed to research in topics: Medicine & Antibody. The author has an hindex of 3, co-authored 3 publications receiving 550 citations.
Papers
More filters
Journal ArticleDOI
Potently neutralizing and protective human antibodies against SARS-CoV-2.
Seth J. Zost,Pavlo Gilchuk,James Brett Case,Elad Binshtein,Rita E. Chen,Joseph P. Nkolola,Alexandra Schäfer,Joseph X. Reidy,Andrew Trivette,Rachel S. Nargi,Rachel E. Sutton,Naveenchandra Suryadevara,David R. Martinez,Lauren E. Williamson,Elaine C. Chen,Taylor Jones,Samuel Day,Luke Myers,Ahmed O. Hassan,Natasha M. Kafai,Emma S. Winkler,Julie M. Fox,Swathi Shrihari,Benjamin K. Mueller,Jens Meiler,Jens Meiler,Abishek Chandrashekar,Noe B. Mercado,James J. Steinhardt,Kuishu Ren,Yueh-Ming Loo,Nicole L. Kallewaard,Broc T. McCune,Shamus P. Keeler,Michael J. Holtzman,Dan H. Barouch,Lisa E. Gralinski,Ralph S. Baric,Larissa B. Thackray,Michael S. Diamond,Robert H. Carnahan,James E. Crowe +41 more
TL;DR: An analysis identifies human monoclonal antibodies that potently neutralize wild-type SARS-CoV-2 and protect animals from disease, including two that synergize in a cocktail, suggesting that these could be candidates for use as therapeutic agents for the treatment of COVID-19 in humans.
Journal ArticleDOI
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans
Yueh Ming Loo,Patrick M. McTamney,Rosalin H. Arends,Michael E. Abram,Anastasia A. Aksyuk,Seme Diallo,Daniel J. Flores,Elizabeth J. Kelly,Kuishu Ren,Richard Roque,Kim Rosenthal,Katie Streicher,Kevin M. Tuffy,Nicholas J. Bond,Owen Cornwell,Jerome Bouquet,Li Cheng,J. Dunyak,Yue Huang,Anton I. Rosenbaum,Venkatesh Pilla Reddy,Hanne Andersen,Robert H. Carnahan,James E. Crowe,Ana I. Kuehne,Andrew S. Herbert,John M. Dye,Helen Bright,Nicole L. Kallewaard,Menelas N. Pangalos,Mark T. Esser +30 more
TL;DR: A combination of two mAbs that simultaneously bind to distinct, nonoverlapping epitopes on the spike protein receptor binding domain to neutralize SARS-CoV-2 are described and AZD7442 is projected to contribute to long-term human protection.
Journal ArticleDOI
Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
James Brett Case,Samantha Mackin,John M. Errico,Zhenlu Chong,Emily A Madden,Bradley M. Whitener,Barbara Guarino,Michael Schmid,Kim Rosenthal,Kuishu Ren,Ha V. Dang,Gyorgy Snell,Ana Jung,Lindsay Droit,Scott A. Handley,Peter Halfmann,Yoshihiro Kawaoka,James E. Crowe,Daved H. Fremont,Herbert W. Virgin,Yueh Ming Loo,Mark T. Esser,Lisa A. Purcell,Davide Corti,Michael S. Diamond +24 more
TL;DR: In this paper , the authors report on the protection of two monoclonal antibody therapies (S309 and AZD7442) against SARS-CoV-2 Omicron lineage strains (BA.1, BA.2, and BA.1.1).
Posted ContentDOI
Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals
Seth J. Zost,Pavlo Gilchuk,James Brett Case,Elad Binshtein,Rita E. Chen,Joseph X. Reidy,Andrew Trivette,Rachel S. Nargi,Rachel E. Sutton,Naveenchandra Suryadevara,Lauren E. Williamson,Elaine C. Chen,Taylor Jones,Samuel Day,Luke Myers,Ahmed O. Hassan,Natasha M. Kafai,Emma S. Winkler,Julie M. Fox,James J. Steinhardt,Kuishu Ren,Yueh-Ming Loo,Nicole L. Kallewaard,David R. Martinez,Alexandra Schäfer,Lisa E. Gralinski,Ralph S. Baric,Larissa B. Thackray,Michael S. Diamond,Robert H. Carnahan,James E. Crowe +30 more
TL;DR: These results identify protective epitopes on the SRBD and provide a structure-based framework for rational vaccine design and the selection of robust immunotherapeutic cocktails.
Posted ContentDOI
The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 B.1.351 and other variants of concern in preclinical studies
Alexandra J. Spencer,Susan J. Morris,Marta Ulaszewska,Claire Powers,Reshma Kailath,Cameron Bissett,A Truby,Nazia Thakur,Nazia Thakur,Joseph Newman,Elizabeth R. Allen,Chang Liu,Chang Liu,Wanwisa Dejnirattisai,Juthathip Mongkolsapaya,Hannah Davies,Francesca R. Donnellan,David Pulido,Thomas P. Peacock,Wendy S. Barclay,Helen Bright,Kuishu Ren,Gavin R. Screaton,P McTammy,Dalan Bailey,Sarah C. Gilbert,Teresa Lambe +26 more
TL;DR: In this article, the authors describe the generation and preclinical assessment of a ChAdOx1-vectored vaccine against the variant of concern B.1.351 (AZD2816).